In the press
IF HENRY FORD WERE IN BIOTECH
IF HENRY FORD WERE IN BIOTECH
Please join us to hear from our CEO, Marc Appel.
Related Press
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio The following was taken from PR Newswire and you can read it here: https://www.prnewswire.com/news-releases/research-bridge-partners-seed-capital-investment-in-asalyxa-bio-advances-dr-lola-eniola-adefesos-immune-cell-targeted-therapeutic-platform-301242853.html “Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Research Bridge Partners – a 501 (c) (3)… Continue reading Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine
Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth “Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration… Continue reading Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine
Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration
Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration to Strengthen Biotech Ecosystem and Support Development and Commercialization of Novel Therapeutics The following excerpt was taken from Globenewswire– continue reading here. Orange Grove Bio, a drug investment and development firm, today announced the establishment of a strategic collaboration with the Magnuson… Continue reading Magnuson Center for Entrepreneurship at Dartmouth College and Orange Grove Bio Establish Collaboration
New York biotech firm moving HQ to Cincinnati
New York biotech firm moving HQ to Cincinnati The following excerpt was taken from Cincyinno Business Journal — continue reading here. A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819 Innovation Hub “A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819… Continue reading New York biotech firm moving HQ to Cincinnati
The University of Pittsburgh and Orange Grove Bio Establish Partnership …
The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration “Orange Grove Bio, a preclinical drug investment and development firm, and… Continue reading The University of Pittsburgh and Orange Grove Bio Establish Partnership …
Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST.
Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST. Please join us to hear from our CEO, Marc Appel.– continue reading here. Upcoming Webinar for Pre-Clinical Biotech Development Opportunities
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area The following excerpt was taken from Cincinnati Enquirer — continue reading here. Orange Grove Bio, a venture capital firm that invests mainly in therapeutic drug companies, is moving its headquarters from the New York City “Orange Grove Bio, a venture capital firm that invests… Continue reading Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Pre-clinical Biotech Development Opportunity Video
Pre-clinical Biotech Development Opportunity Video
IpiNovyx Bio closes $10 million seed financing round
IpiNovyx Bio closes $10 million seed financing round The below is an excerpt taken from EndPoints News about our portfolio company, Ipinovyx Bio. The following excerpt was taken from EndPonts News — continue reading here. “With a focus on autoimmune and inflammatory diseases, IpiNovyx Bio closed a $10 million seed financing round “With a focus… Continue reading IpiNovyx Bio closes $10 million seed financing round